메뉴 건너뛰기




Volumn 21, Issue 3, 2007, Pages 187-198

Composite endpoints for clinical trials: Current perspectives

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPTIFIBATIDE; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN; MISOPROSTOL; PAMIDRONIC ACID; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; VALSARTAN;

EID: 34249821368     PISSN: 13649027     EISSN: 14735679     Source Type: Journal    
DOI: 10.2165/00124363-200721030-00001     Document Type: Review
Times cited : (26)

References (77)
  • 1
    • 26844517347 scopus 로고    scopus 로고
    • Key issues in end point selection for heart failure trials: Composite end points
    • Neaton JD, Gray G, Zuckerman BD, et al. Key issues in end point selection for heart failure trials: composite end points. J Cardiac Failure 2005; 11: 567-75
    • (2005) J Cardiac Failure , vol.11 , pp. 567-575
    • Neaton, J.D.1    Gray, G.2    Zuckerman, B.D.3
  • 2
    • 34249824093 scopus 로고    scopus 로고
    • International Conference on Harmonisation, trials [online, Available from URL:, Accessed Jan 23
    • International Conference on Harmonisation. ICH harmonized tripartite guideline E9: statistical principals for clinical trials [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA485.pdf [Accessed 2007 Jan 23]
    • (2007) ICH harmonized tripartite guideline E9: Statistical principals for clinical
  • 4
    • 0036169930 scopus 로고    scopus 로고
    • Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update
    • American College of Rheumatology
    • American College of Rheumatology. Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46
    • (2002) Arthritis Rheum , vol.46 , pp. 328-346
  • 5
    • 0037108042 scopus 로고    scopus 로고
    • Combined endpoints: Can we use them?
    • Lubsen J, Kirwan B-A. Combined endpoints: can we use them? Stat Med 2002; 21: 2959-70
    • (2002) Stat Med , vol.21 , pp. 2959-2970
    • Lubsen, J.1    Kirwan, B.-A.2
  • 6
    • 24344484767 scopus 로고    scopus 로고
    • The disability rating and coma/near-coma scales in evaluating severe head injury
    • Rappaport M. The disability rating and coma/near-coma scales in evaluating severe head injury. Neuropsychol Rehabil 2005; 15: 442-53
    • (2005) Neuropsychol Rehabil , vol.15 , pp. 442-453
    • Rappaport, M.1
  • 7
    • 0018099294 scopus 로고
    • Severe psoriasis: Oral therapy with a new retinoid
    • Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44
    • (1978) Dermatologica , vol.157 , pp. 238-244
    • Fredriksson, T.1    Pettersson, U.2
  • 8
    • 33645227163 scopus 로고    scopus 로고
    • Some issues with composite endpoints in clinical trials
    • Chi GYH. Some issues with composite endpoints in clinical trials. Fundam Clin Pharmacol 2005; 19: 609-19
    • (2005) Fundam Clin Pharmacol , vol.19 , pp. 609-619
    • Chi, G.Y.H.1
  • 9
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
    • (2002) Lancet , vol.359 , pp. 995-1003
    • Dahlöf, B.1    Devereux, R.B.2    Kjeldsen, S.E.3
  • 10
    • 0035818884 scopus 로고    scopus 로고
    • A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    • for the Valsartan Heart Failure Investigators
    • Cohn JN, Tognoni G, for the Valsartan Heart Failure Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75
    • (2001) N Engl J Med , vol.345 , pp. 1667-1675
    • Cohn, J.N.1    Tognoni, G.2
  • 11
    • 0035804846 scopus 로고    scopus 로고
    • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial
    • Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8
    • (2001) JAMA , vol.285 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3
  • 12
    • 33748748206 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
    • for the DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
    • Gerstein HC, Yusuf S, Pogue J, et al. for the DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105
    • (2006) Lancet , vol.368 , pp. 1096-1105
    • Gerstein, H.C.1    Yusuf, S.2    Pogue, J.3
  • 13
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial
    • Dormandy JA, Charbonnel B, Eckland DA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.A.3
  • 14
    • 0035922447 scopus 로고    scopus 로고
    • Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    • Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
    • (2001) N Engl J Med , vol.345 , pp. 851-860
    • Lewis, E.J.1    Hunsicker, L.G.2    Clarke, W.R.3
  • 15
    • 9244246780 scopus 로고    scopus 로고
    • Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients
    • Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532-40
    • (2004) Transplantation , vol.78 , pp. 1532-1540
    • Vitko, S.1    Margreiter, R.2    Weimar, W.3
  • 16
    • 0029162250 scopus 로고
    • Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
    • Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9
    • (1995) Ann Intern Med , vol.123 , pp. 241-249
    • Silverstein, F.E.1    Graham, D.Y.2    Senior, J.R.3
  • 17
    • 0033050818 scopus 로고    scopus 로고
    • Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
    • Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17: 846-54
    • (1999) J Clin Oncol , vol.17 , pp. 846-854
    • Theriault, R.L.1    Lipton, A.2    Hortobagyi, G.N.3
  • 18
    • 0344033647 scopus 로고    scopus 로고
    • The olanzapine relapse prevention study group: A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
    • Beasley CM, Sutton VK, Hamilton SH, et al. The olanzapine relapse prevention study group: a double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003; 23: 582-94
    • (2003) J Clin Psychopharmacol , vol.23 , pp. 582-594
    • Beasley, C.M.1    Sutton, V.K.2    Hamilton, S.H.3
  • 19
    • 0037872688 scopus 로고    scopus 로고
    • Composite outcomes in randomized trials: Greater precision but with greater uncertainty?
    • Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289: 2554-9
    • (2003) JAMA , vol.289 , pp. 2554-2559
    • Freemantle, N.1    Calvert, M.2    Wood, J.3
  • 20
    • 0030670453 scopus 로고    scopus 로고
    • Clinical perspectives on the use of composite endpoints
    • Cannon CP. Clinical perspectives on the use of composite endpoints. Control Clin Trials 1997; 18: 517-29
    • (1997) Control Clin Trials , vol.18 , pp. 517-529
    • Cannon, C.P.1
  • 21
    • 0037036961 scopus 로고    scopus 로고
    • Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial
    • Fox KAA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002; 360: 743-51
    • (2002) Lancet , vol.360 , pp. 743-751
    • Fox, K.A.A.1    Poole-Wilson, P.A.2    Henderson, R.A.3
  • 22
    • 0035934575 scopus 로고    scopus 로고
    • Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): A randomised trial
    • The TIME Investigators
    • The TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001; 358: 951-7
    • (2001) Lancet , vol.358 , pp. 951-957
  • 23
    • 0033575989 scopus 로고    scopus 로고
    • Dofetilide in patients with congestive heart failure and left ventricular dysfunction
    • Torp-Pederson C, Moller M, Bloch-Thomsen P, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857-65
    • (1999) N Engl J Med , vol.341 , pp. 857-865
    • Torp-Pederson, C.1    Moller, M.2    Bloch-Thomsen, P.3
  • 25
    • 0037636758 scopus 로고    scopus 로고
    • Clinical trials: Multiple treatments, multiple end points, and multiple lessons
    • Lauer MS, Topol AJ. Clinical trials: multiple treatments, multiple end points, and multiple lessons. JAMA 2003; 289: 2575-7
    • (2003) JAMA , vol.289 , pp. 2575-2577
    • Lauer, M.S.1    Topol, A.J.2
  • 26
    • 33646596912 scopus 로고    scopus 로고
    • Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial
    • The ESPRIT Study Group
    • The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73
    • (2006) Lancet , vol.367 , pp. 1665-1673
  • 27
    • 0031029373 scopus 로고    scopus 로고
    • Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
    • Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-82
    • (1997) Lancet , vol.349 , pp. 675-682
    • Cairns, J.A.1    Connolly, S.J.2    Roberts, R.3
  • 28
    • 0031026945 scopus 로고    scopus 로고
    • Dead is dead: Artificial definitions are no substitute
    • Gottlieb SS. Dead is dead: artificial definitions are no substitute. Lancet 1997; 349: 662-3
    • (1997) Lancet , vol.349 , pp. 662-663
    • Gottlieb, S.S.1
  • 29
    • 0141918127 scopus 로고    scopus 로고
    • Committee for Proprietary Medicinal Products CPMP, CPMP/EWP/908/99. London, 19 Dec, online, Available from URL:, Accessed Jan 23
    • Committee for Proprietary Medicinal Products (CPMP). Points to consider on multiplicity issues in clinical trials. CPMP/EWP/908/99. London, 19 Dec 2002 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/090899en. pdf [Accessed 2007 Jan 23]
    • (2002) Points to consider on multiplicity issues in clinical trials
  • 30
    • 0033600275 scopus 로고    scopus 로고
    • Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease
    • Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-7
    • (1999) N Engl J Med , vol.340 , pp. 1941-1947
    • Niewoehner, D.E.1    Erbland, M.L.2    Deupree, R.H.3
  • 31
    • 0026011647 scopus 로고
    • Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The cardiac arrhythmia suppression trial
    • Echt DS, Liebson PR, Mitchell IB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial. N Engl J Med 1991; 324: 781-8
    • (1991) N Engl J Med , vol.324 , pp. 781-788
    • Echt, D.S.1    Liebson, P.R.2    Mitchell, I.B.3
  • 32
    • 10544251442 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE Trial
    • Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Circulation 1996; 94: 2793-9
    • (1996) Circulation , vol.94 , pp. 2793-2799
    • Packer, M.1    Colucci, W.S.2    Sackner-Bernstein, J.D.3
  • 33
    • 0028223488 scopus 로고
    • Exercise testing as outcome in congestive heart failure trials: Design considerations when interpreting results
    • Lubsen J. Exercise testing as outcome in congestive heart failure trials: design considerations when interpreting results. Drugs 1994; 47: 25-30
    • (1994) Drugs , vol.47 , pp. 25-30
    • Lubsen, J.1
  • 34
    • 0030723636 scopus 로고    scopus 로고
    • Clinical trials with multiple outcomes: A statistical perspective on their design, analysis, and interpretation
    • Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials 1997; 18: 530-45
    • (1997) Control Clin Trials , vol.18 , pp. 530-545
    • Pocock, S.J.1
  • 35
    • 0032511580 scopus 로고    scopus 로고
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
    • (1998) BMJ , vol.317 , pp. 703-713
  • 36
    • 0032716833 scopus 로고    scopus 로고
    • Diabetes and cardiovascular disease: Current opinions and future directions
    • McGuire DK, Califf RM. Diabetes and cardiovascular disease: current opinions and future directions. Am Heart J 1999; 138 (5 Pt 1): S327-9
    • (1999) Am Heart J , vol.138 , Issue.5 PART 1
    • McGuire, D.K.1    Califf, R.M.2
  • 37
    • 33747813779 scopus 로고    scopus 로고
    • FDA, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research CBER, April, online, Available from URL:, Accessed Jan 23
    • FDA, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Draft guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. April 2005 [online]. Available from URL: http://www.fda.gov/cder/Guidance/6592dft.pdf [Accessed 2007 Jan 23]
    • (2005) Draft guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics
  • 38
    • 0037986306 scopus 로고    scopus 로고
    • End points and United States Food and Drug Administration approval of oncology drugs
    • Johnson JR, Williams G, Pazdur R, et al. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21: 1404-11
    • (2003) J Clin Oncol , vol.21 , pp. 1404-1411
    • Johnson, J.R.1    Williams, G.2    Pazdur, R.3
  • 39
    • 18144385438 scopus 로고    scopus 로고
    • Multiplicity in randomized trials I: Endpoints and treatments
    • Schulz KF, Grimes DA. Multiplicity in randomized trials I: endpoints and treatments. Lancet 2005; 365: 1591-5
    • (2005) Lancet , vol.365 , pp. 1591-1595
    • Schulz, K.F.1    Grimes, D.A.2
  • 40
    • 34247503838 scopus 로고    scopus 로고
    • Problems with the use of composite endpoints in cardiovascular trials: Systematic review of randomised controlled trials
    • Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, et al. Problems with the use of composite endpoints in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007; 334: 786-8
    • (2007) BMJ , vol.334 , pp. 786-788
    • Ferreira-Gonzalez, I.1    Busse, J.W.2    Heels-Ansdell, D.3
  • 41
    • 33845200819 scopus 로고    scopus 로고
    • The DREAM trial [comment]
    • Yudkin JS. The DREAM trial [comment]. Lancet 2006; 368: 2049-50
    • (2006) Lancet , vol.368 , pp. 2049-2050
    • Yudkin, J.S.1
  • 42
    • 33845200819 scopus 로고    scopus 로고
    • The DREAM trial [comment]
    • Nissen SE. The DREAM trial [comment]. Lancet 2006; 368: 2049
    • (2006) Lancet , vol.368 , pp. 2049
    • Nissen, S.E.1
  • 43
    • 0026549639 scopus 로고
    • A method of assigning scores to the components of a composite outcome: An example from the MITI trial
    • Hallstrom AP, Litwin PE, Weaver WD. A method of assigning scores to the components of a composite outcome: an example from the MITI trial. Control Clin Trials 1992; 13: 148-55
    • (1992) Control Clin Trials , vol.13 , pp. 148-155
    • Hallstrom, A.P.1    Litwin, P.E.2    Weaver, W.D.3
  • 44
    • 0028076195 scopus 로고
    • Considerations in choice of a clinical endpoint for AIDS clinical trials
    • Neaton JD, Wentworth DN, Rhame F, et al. Considerations in choice of a clinical endpoint for AIDS clinical trials. Stat Med 1994; 13: 2107-25
    • (1994) Stat Med , vol.13 , pp. 2107-2125
    • Neaton, J.D.1    Wentworth, D.N.2    Rhame, F.3
  • 45
    • 0034013393 scopus 로고    scopus 로고
    • A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group
    • Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Gen Psychiatry 2000; 57: 481-9
    • (2000) Gen Psychiatry , vol.57 , pp. 481-489
    • Bowden, C.L.1    Calabrese, J.R.2    McElroy, S.L.3
  • 46
    • 2442479695 scopus 로고    scopus 로고
    • Bristow MR, Saxon LA, Boehmer J, et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50
    • Bristow MR, Saxon LA, Boehmer J, et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50
  • 47
    • 0034729993 scopus 로고    scopus 로고
    • Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
    • Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72
    • (2000) Lancet , vol.356 , pp. 366-372
    • Brown, M.J.1    Palmer, C.R.2    Castaigne, A.3
  • 48
    • 0034730027 scopus 로고    scopus 로고
    • Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
    • Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65
    • (2000) Lancet , vol.356 , pp. 359-365
    • Hansson, L.1    Hedner, T.2    Lund-Johansen, P.3
  • 49
    • 34249792211 scopus 로고    scopus 로고
    • Committee for Medicinal Products for Human Use (CHMP). Guideline on data monitoring committees: EMEA/CHMP/EWP/5872/03. London, 27 Jul 2005 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/587203en.pdf [Accessed 2007 Jan 23]
    • Committee for Medicinal Products for Human Use (CHMP). Guideline on data monitoring committees: EMEA/CHMP/EWP/5872/03. London, 27 Jul 2005 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/587203en.pdf [Accessed 2007 Jan 23]
  • 50
    • 34249806835 scopus 로고    scopus 로고
    • FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH). Draft guidance for clinical trial sponsors. On the establishment and operation of clinical trial data monitoring committees. 2001 Nov [online]. Available from URL: http://http://www.fda.gov/cber/gdlns/clindatmon.pdf [Accessed 2007 Jan 23]
    • FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH). Draft guidance for clinical trial sponsors. On the establishment and operation of clinical trial data monitoring committees. 2001 Nov [online]. Available from URL: http://http://www.fda.gov/cber/gdlns/clindatmon.pdf [Accessed 2007 Jan 23]
  • 51
    • 0030762734 scopus 로고    scopus 로고
    • A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: A double-blind, randomized, dose-finding study
    • The Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group
    • The Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomized, dose-finding study. Eur Heart J 1997; 18: 1416-25
    • (1997) Eur Heart J , vol.18 , pp. 1416-1425
  • 52
    • 0033135701 scopus 로고    scopus 로고
    • The impact of an end-point committee in large multicentre, randomized, placebo-controlled clinical trial
    • Näslund U, Grip L, Fischer-Hansen J, et al. The impact of an end-point committee in large multicentre, randomized, placebo-controlled clinical trial. Eur Heart J 1999; 20: 771-7
    • (1999) Eur Heart J , vol.20 , pp. 771-777
    • Näslund, U.1    Grip, L.2    Fischer-Hansen, J.3
  • 53
    • 0036480190 scopus 로고    scopus 로고
    • Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial: Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial
    • Mahaffey KW, Roe MT, Dyke CK, et al. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial: misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 2002; 143: 242-8
    • (2002) Am Heart J , vol.143 , pp. 242-248
    • Mahaffey, K.W.1    Roe, M.T.2    Dyke, C.K.3
  • 54
    • 17944370493 scopus 로고    scopus 로고
    • Systematic adjudication of myocardial infarction end-points in an international clinical trial
    • Mahaffey KW, Harrington RA, Akkerhuis M, et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2001; 2: 180-6
    • (2001) Curr Control Trials Cardiovasc Med , vol.2 , pp. 180-186
    • Mahaffey, K.W.1    Harrington, R.A.2    Akkerhuis, M.3
  • 55
    • 33645109297 scopus 로고    scopus 로고
    • PROactive results overstated and misleading
    • Skyler JS. PROactive results overstated and misleading. DOC News 2005; 2: 4
    • (2005) DOC News
    • Skyler, J.S.1
  • 56
    • 3042714528 scopus 로고    scopus 로고
    • The prospective pioglitazone clinical trial in macrovascular events (PROactive). Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients
    • Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive). Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 2004; 27: 1647-53
    • (2004) Diabetes Care , vol.27 , pp. 1647-1653
    • Charbonnel, B.1    Dormandy, J.2    Erdmann, E.3
  • 57
    • 33645729862 scopus 로고    scopus 로고
    • PROactive study
    • The PROactive Study Executive Committee and Data and Safety Monitoring Committee
    • The PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study. Lancet 2006; 367: 982
    • (2006) Lancet , vol.367 , pp. 982
  • 58
    • 0042330455 scopus 로고    scopus 로고
    • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial the EUROPA study, Lancet 2003; 362: 782-8
    • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8
  • 59
    • 0034762257 scopus 로고    scopus 로고
    • Intention-to-treat principle
    • Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ 2001; 165: 1339-41
    • (2001) CMAJ , vol.165 , pp. 1339-1341
    • Montori, V.M.1    Guyatt, G.H.2
  • 60
    • 33751313903 scopus 로고    scopus 로고
    • Variable impact of combining fatal and nonfatal endpoints in heart failure trials
    • Skali H, Pfeffer MA, Lubsen J. Variable impact of combining fatal and nonfatal endpoints in heart failure trials. Circulation 2006; 114: 2298-303
    • (2006) Circulation , vol.114 , pp. 2298-2303
    • Skali, H.1    Pfeffer, M.A.2    Lubsen, J.3
  • 61
    • 33845212859 scopus 로고    scopus 로고
    • The DREAM trial [comment]
    • Lubsen J, Poole-Wilson PA. The DREAM trial [comment]. Lancet 2006; 368: 2050
    • (2006) Lancet , vol.368 , pp. 2050
    • Lubsen, J.1    Poole-Wilson, P.A.2
  • 62
    • 19744380776 scopus 로고    scopus 로고
    • Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    • Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102
    • (2005) N Engl J Med , vol.352 , pp. 1092-1102
    • Bresalier, R.S.1    Sandler, R.S.2    Quan, H.3
  • 63
    • 33745929924 scopus 로고    scopus 로고
    • Time-to-event analyses for long-term treatments: The APPROVe Trial
    • Lagakos SW. Time-to-event analyses for long-term treatments: the APPROVe Trial. N Engl J Med 2006; 355: 113-7
    • (2006) N Engl J Med , vol.355 , pp. 113-117
    • Lagakos, S.W.1
  • 64
    • 4544304433 scopus 로고    scopus 로고
    • Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial
    • Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-57
    • (2004) Lancet , vol.364 , pp. 849-857
    • Poole-Wilson, P.A.1    Lubsen, J.2    Kirwan, B.A.3
  • 65
    • 10044246134 scopus 로고    scopus 로고
    • Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction
    • Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-8
    • (2004) N Engl J Med , vol.351 , pp. 2481-2488
    • Hohnloser, S.H.1    Kuck, K.H.2    Dorian, P.3
  • 66
    • 0037306242 scopus 로고    scopus 로고
    • Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis
    • Chen YHJ, DeMets DL, Lan KKG. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Control Clin Trials 2003; 24: 16-27
    • (2003) Control Clin Trials , vol.24 , pp. 16-27
    • Chen, Y.H.J.1    DeMets, D.L.2    Lan, K.K.G.3
  • 67
    • 0029937949 scopus 로고    scopus 로고
    • The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
    • Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55
    • (1996) N Engl J Med , vol.334 , pp. 1349-1355
    • Packer, M.1    Bristow, M.R.2    Cohn, J.N.3
  • 68
    • 0033011501 scopus 로고    scopus 로고
    • Carvedilol and the Food and Drug Administration (FDA) approval process: An introduction
    • Fisher LD, Moye LA. Carvedilol and the Food and Drug Administration (FDA) approval process: an introduction. Control Clin Trials 1999; 20: 1-15
    • (1999) Control Clin Trials , vol.20 , pp. 1-15
    • Fisher, L.D.1    Moye, L.A.2
  • 69
    • 0032971979 scopus 로고    scopus 로고
    • Carvedilol and the Food and Drug Administration (FDA) approval process: The FDA paradigm and reflections on hypothesis testing
    • Fisher LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. Control Clin Trials 1999; 20: 16-39
    • (1999) Control Clin Trials , vol.20 , pp. 16-39
    • Fisher, L.D.1
  • 70
    • 34249798560 scopus 로고    scopus 로고
    • Stopping a trial early for treatment benefit: Pros and cons
    • Jan
    • Kleist P. Stopping a trial early for treatment benefit: pros and cons. Appl Clin Trials 2007; Jan: 34-7
    • (2007) Appl Clin Trials , pp. 34-37
    • Kleist, P.1
  • 71
    • 27644487803 scopus 로고    scopus 로고
    • Randomized trials stopped early for benefit: A systematic review
    • Montori VM, Devereaux PJ, Adhikari NKJ, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294: 2203-9
    • (2005) JAMA , vol.294 , pp. 2203-2209
    • Montori, V.M.1    Devereaux, P.J.2    Adhikari, N.K.J.3
  • 72
    • 0035810547 scopus 로고    scopus 로고
    • Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
    • The CAPRICORN Investigators
    • The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-90
    • (2001) Lancet , vol.357 , pp. 1385-1390
  • 73
    • 0033937362 scopus 로고    scopus 로고
    • Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction
    • Brown DL, Fann CSJ, Chang CJ. Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction. Cardiovasc Drugs Ther 2000; 14: 253-8
    • (2000) Cardiovasc Drugs Ther , vol.14 , pp. 253-258
    • Brown, D.L.1    Fann, C.S.J.2    Chang, C.J.3
  • 74
    • 34247495694 scopus 로고    scopus 로고
    • Composite and surrogate outcomes in randomised controlled trials
    • Freemantle N, Calvert M. Composite and surrogate outcomes in randomised controlled trials. BMJ 2007; 334: 756-7
    • (2007) BMJ , vol.334 , pp. 756-757
    • Freemantle, N.1    Calvert, M.2
  • 75
    • 0035869324 scopus 로고    scopus 로고
    • Stenting versus thrombolysis in acute myocardial infarction trial (STAT)
    • Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001; 37: 985-91
    • (2001) J Am Coll Cardiol , vol.37 , pp. 985-991
    • Le May, M.R.1    Labinaz, M.2    Davies, R.F.3
  • 76
    • 33744729483 scopus 로고    scopus 로고
    • Multiple endpoints: Statistical framework for clinical decision making
    • Jun 15-19; San Antonio TX
    • Temple R. Multiple endpoints: statistical framework for clinical decision making. Drug Information Association 39th Annual Meeting; 2003 Jun 15-19; San Antonio (TX).
    • (2003) Drug Information Association 39th Annual Meeting
    • Temple, R.1
  • 77
    • 0035901579 scopus 로고    scopus 로고
    • The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
    • Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-94
    • (2001) Ann Intern Med , vol.134 , pp. 663-694
    • Altman, D.G.1    Schulz, K.F.2    Moher, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.